Filing Flows › Companies › Scientist Home Future Health › Cash flow
Scientist Home Future Health cash flow, quarter by quarter
Latest: Q3 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$45K in Q3 2026 · −$268K over twelve months
Analysis
In Q3 2026, Scientist Home Future Health generated −$45K of operating cash flow. That is $55K more than in Q3 2025 (−$99K).
Over the twelve months to Sep 30, 2026, operating cash flow was −$268K; the largest uses were operating cash flow ($268K); besides operations, cash came from other financing ($82K); the cash balance fell by $187K.
Operating cash flow was −$45K against net income of $8K — -5.4× profit, less cash than reported earnings, worth checking against working capital. The largest differences: inventory −$95K, payables +$66K, depreciation & amortization +$4K.
Free cash flow
Cash runway and the debt wall
Scientist Home Future Health is burning cash: its operations consume cash, a free cash flow of −$268K a year at the current rate against $14K of cash and investments: a runway of about 1 month before any new financing.
Where the cash came from and went
From profit to cash
Every quarter
| Quarter | Operating cash flow | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|
| Q3 2026 | −$45K | — | −$5K | −$45K |
| Q2 2026 | −$13K | — | $6K | −$13K |
| Q1 2026 | −$72K | — | $54K | −$72K |
| Q4 2025 | −$139K | — | $132K | −$139K |
| Q3 2025 | −$99K | $266K | −$164K | −$99K |
| Q2 2025 | −$5K | — | −$95K | −$5K |
| Q1 2025 | −$5K | — | $2K | −$5K |
| Q4 2024 | $9K | — | $340 | $9K |
Scientist Home Future Health: income statement and cash flow
Scientist Home Future Health, Q3 2026: revenue $212K (+435% year over year), operating margin 3.9%. The chart follows the revenue to costs, profit and cash.
Scientist Home Future Health: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.